close
Enquiry IconContact Us
Logo

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Regenerative medicines are medical products or active pharmaceutical ingredients that have the ability to cure organs and tissues organs damaged by various factors such as aging, trauma, and can also be used to provide stability of health in congenital disorders such as cerebral palsy, Fragile X syndrome and Down syndrome. Regenerative medicines are useful in treating both chronic and acute disorders, in terms of various abnormalities such as cardiovascular diseases, dermal wounds, and in the treatment of certain types of cancer. Furthermore, the current therapy of organ and tissue transplantation for treating organ and tissue failures can result in patient death due to limited or no donor supply and often results in severe complications in immune system. Regenerative medicine helps to alleviate such issues to a major extent. Regenerative medicine include development of methods to regrow, repair or replace either the damaged or diseased cells, and organs or tissues. This medicinal branch includes generation and usage of stem cells and tissue engineering.

Figure 1. Global Regenerative Medicine (Bone and Joint) Market Value (US$ Mn), 2016-2027

Regenerative Medicine (Bone and Joint)  | Coherent Market Insights

Global regenerative medicine (Bone and Joint) market size is estimated to be valued at US$ 7,090.1million in 2020 and is expected to exhibit a CAGR of 10.3% over the forecast period (2020-2027).

Regulatory authorities and government organizations are engaged in launching various programs, in order to boost growth of the global regenerative medicine (bone and joint) market. For instance, in January 2017, the U.S. Food and Drug Administration (FDA) launched a new designation program for regenerative medicine therapies. This ‘Regenerative Medicine Therapy (RMAT) Designation’ program will foster the approval and development of regenerative medicine products.

request-sample

Regenerative Medicine (Bone and Joint) Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 7,090.1 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 10.3% 2027 Value Projection: US$ 14,074.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Technology: Stem Cell, Biomaterial, Tissue Engineering.
  • By Application: Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Bones, Autogenic Bones, Others.
Companies covered:

Anika Therapeutics, Inc, Arthrex, Inc., Baxter International, Inc., CONMED Corporation, Johnson & Johnson, Medtronic, Plc, Smith & Nephew plc, Stryker Corporation, Zimmer Holdings, Inc., Aziyo Biologics, and Ortho Regenerative Technologies Inc.

Growth Drivers:
  • Increasing product approvals and launches by key companies
  • Key companies focusing on research and development of stem and gene therapies
  • Increasing Number of bone and joint disorders and orthopaedic surgeries globally
Restraints & Challenges:
  • Stringent government regulatory scenario in research and development of regenerative medicines
  • Post implant failures and infections

Global Regenerative Medicine (Bone and Joint) Market- Impact of Coronavirus (Covid-19) Pandemic

The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020.  According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization: January 10, 2021, globally over 109 Million cases were reported on 15th February 2021.

Moreover, the COVID-19 pandemic has impacted negatively on the clinical trials of various new drug molecules, treatments, and therapies, which is expected to affect the global regenerative medicine (Bone and Joint) market. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the commencement of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others.

According to National Center for Biotechnology Information (NCBI), April 29, 2020, across the cell and gene therapy sector, research programs and preclinical activities have been disrupted, as the companies have reduced the number of people working on the site to keep them safe. Around 85% of the cell and gene therapy companies’ employees are working from home for several weeks, which is one of the reasons for the delay in the commencement  of the trials. Moreover, lack of laboratory consumables, personal protective equipment (PPE), and reagents are some of the reasons for the delay in the commencement of clinical trials.

According to National Center for Biotechnology Information (NCBI), April 29, 2020, many clinical trials suspended the trial enrolment, in order to minimize the risk of contracting COVID-19 and this has led to the delay in the activation of new clinical trials. Moreover, many companies have already missed the follow-up for the patients already in trials. Furthermore, travel restrictions, patient concerns of contracting coronavirus infection, and others are some of the factors responsible for the withdrawal of patients from the clinical trial.

Figure 2. Global Regenerative Medicine (Bone and Joint) Market Share (%) by Region, 2020

Regenerative Medicine (Bone and Joint)  | Coherent Market Insights

In North America, increasing number of product approvals by regulatory authorities is expected to drive the regenerative medicine (Bone and Joint) market growth in the region, over the forecast period. For instance, in September 2019, Medtronic plc announced U.S. FDA approval of its prospective, randomized pivotal clinical trial for the use of Infuse Bone Graft in Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures. A TLIF is a type of surgery that fuses or joins bones of the spine through a posterior approach.

Moreover, in Europe, market players are focused on opening new manufacturing facilities for research and development of regenerative medicines, in order to expand their geographical footprint, which is expected to create a lucrative environment for the market growth. For instance, on November 3, 2020, Minaris regenerative medicine (Bone and Joint), a contract development and manufacturing organization, announced to open a new facility in Ottobrunn, Germany, for the development and manufacturing services for cell and gene therapies. The new facility will be operational in 2023

Furthermore, regulatory constraints such as companies should follow  good manufacturing practice (GMP) guidelines and good tissue practice (GTP) guidelines while developing regenerative medicines are expected to hinder growth of the global regenerative medicine (bone and joint) market. Human cellular and tissue-based products are considered as biologics. All regenerative medicine products used in bone and joint reconstructive surgeries must meet criteria of good manufacturing practice (GMP) guidelines and good tissue practice (GTP) guidelines. The Office of Cellular, Tissue, and Gene Therapies (OCTGT) of the U.S. FDA regulates and monitors regenerative medicine products in the U.S. OCTGT has the responsibility of monitoring gene therapy, tissue engineering, tissue cellular therapy, and cellular gene therapy products.

Key Players

Major players operating in global regenerative medicine (Bone and Joint) market include Anika Therapeutics, Inc, Arthrex, Inc., Baxter International, Inc., CONMED Corporation, Johnson & Johnson, Medtronic, Plc, Smith & Nephew plc, Stryker Corporation, Zimmer Holdings, Inc., Aziyo Biologics, and Ortho Regenerative Technologies Inc.

Regenerative medicine is a biological heterogeneous domain that incorporates material science, engineering, medicine, biological science, and surgery. It acts therapeutically by augmenting and stimulating the body’s capacity for regeneration and self-repair. Regenerative medicine involves the development of methods to regrow, repair or replace either the damaged or diseased cells, organs or tissues. This medicinal branch includes the generation and usage of stem cells and tissue engineering.

Moreover, Major players in the market are also focused on expanding their capabilities. For instance, in March 2020, BioStem Life Sciences, a subsidiary of BioStem Technologies Inc. and a developer of regenerative therapies, announced to add R&D laboratory to its Florida, U.S. facility.

Market Dynamics

Key companies focusing on product approvals in regenerative medicine is expected to drive the global regenerative medicine (Bone and Joint) market growth. For instance, in 2017, Karl Schumacher Dental, LLC launched its new range of regenerative products, which include allograft, xenograft, and synthetic and collagen membranes.

Moreover, adoption of 3D printing technology in regenerative medicine (bone and joint) is expected to aid in growth of the global regenerative medicine (bone and joint) market. For instance, in February 2020, researchers from Wake Forest School of Medicine, U.S. reported investigation of the effects of neural cell integration into the bioprinted skeletal muscle construct to accelerate functional muscle regeneration in vivo.

Furthermore, High prevalence of arthritis is expected to propel growth of the global regenerative medicine (bone and joint) market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC)’s May 2019 report, around 54.4 million U.S. adults had diagnosed arthritis, which accounted for around 1 in 4 people in the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global regenerative medicine (bone and joint) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, regional outlook, and competitive strategies adopted by the leading players.
  • It profiles leading players in the global regenerative medicine (bone and joint) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansions and marketing tactics
  • The global regenerative medicine (bone and joint) market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
  • The key players operating in global regenerative medicine (Bone and Joint) market include Anika Therapeutics, Inc, Arthrex, Inc., Baxter International, Inc., CONMED Corporation, Johnson & Johnson, Medtronic, Plc, Smith & Nephew plc, Stryker Corporation, Zimmer Holdings, Inc., Aziyo Biologics, and Ortho Regenerative Technologies Inc.
  • Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global regenerative medicine (bone and joint) market

Detailed Segmentation:

  • Global Regenerative Medicine (Bone and Joint) Market, By Technology :
    • Stem Cell
    • Biomaterial
    • Tissue Engineering
  • Global Regenerative Medicine (Bone and Joint) Market, By Application :
    • Bone Graft Substitutes
    • Osteoarticular Diseases
    • Allogeneic Bones
    • Autogenic Bones
    • Others 
  • Global Regenerative Medicine (Bone and Joint) Market, By Region:
    • By Technology:
      • Stem Cell
      • Biomaterial
      • Tissue Engineering
    • By Application :
      • Bone Graft Substitutes
      • Osteoarticular Diseases
      • Allogeneic Bones
      • Autogenic Bones
      • Others 
    • By Country:
      • U.S.
      • Canada
    • By Technology:
      • Stem Cell
      • Biomaterial
      • Tissue Engineering
    • By Application :
      • Bone Graft Substitutes
      • Osteoarticular Diseases
      • Allogeneic Bones
      • Autogenic Bones
      • Others 
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • By Technology:
      • Stem Cell
      • Biomaterial
      • Tissue Engineering
    • By Application :
      • Bone Graft Substitutes
      • Osteoarticular Diseases
      • Allogeneic Bones
      • Autogenic Bones
      • Others 
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • By Technology:
      • Stem Cell
      • Biomaterial
      • Tissue Engineering
    • By Application :
      • Bone Graft Substitutes
      • Osteoarticular Diseases
      • Allogeneic Bones
      • Autogenic Bones
      • Others 
    • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • By Technology:
      • Stem Cell
      • Biomaterial
      • Tissue Engineering
    • By Application :
      • Bone Graft Substitutes
      • Osteoarticular Diseases
      • Allogeneic Bones
      • Autogenic Bones
      • Others 
    • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • By Technology:
      • Stem Cell
      • Biomaterial
      • Tissue Engineering
    • By Application :
      • Bone Graft Substitutes
      • Osteoarticular Diseases
      • Allogeneic Bones
      • Autogenic Bones
      • Others 
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
    • Anika Therapeutics, Inc.*
    • Arthrex, Inc.
    • Baxter International, Inc.
    • CONMED Corporation
    • Johnson & Johnson
    • Medtronic, Plc
    • Smith & Nephew plc
    • Stryker Corporation
    • Zimmer Holdings, Inc.
    • Aziyo Biologics
    • Ortho Regenerative Technologies Inc

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Technology
      • Market Snippet, By Application
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
  4. Global Regenerative Medicine (Bone and Joint) Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact of Covid-19 on Clinical Trials
    • Government Initiatives
  5. Global Regenerative Medicine (Bone and Joint) Market, By Technology, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017– 2027
      • Segment Trends
        • Stem Cell
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Biomaterial
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Tissue Engineering
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  6. Global Regenerative Medicine (Bone and Joint) Market, By Application, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017– 2027
      • Segment Trends
        • Bone Graft Substitutes
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Osteoarticular Diseases
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Allogeneic Bones
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Allogeneic Bones
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  7. Global Regenerative Medicine (Bone and Joint) Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Technology, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Technology, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Technology, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Technology, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Technology, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2020–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Technology, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2020–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2020–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • Anika Therapeutics, Inc
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Arthrex, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Baxter International, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CONMED Corporation
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Medtronic, Plc
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Smith & Nephew plc
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Stryker Corporation
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Zimmer Holdings, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aziyo Biologics
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ortho Regenerative Technologies Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 26 market data tables and 25 figures on “Regenerative Medicine (Bone and Joint) Market– Global forecast to 2027”.

FAQgrowicon

Frequently Asked Questions

The global regenerative medicine (Bone and Joint) market is estimated to be valued at US$ 7,090.1 million in 2020 and is expected to exhibit a CAGR of 10.3% between 2020 and 2027.
Increasing product approvals and launches by key companies, key companies focusing on research and development of stem and gene therapies, and increasing number of bone and joint disorders and orthopaedic surgeries globally.
Biomaterial segment is estimated to hold major market share in 2020, owing to the increasing development and launches of innovative regenerative medicines.
Bone graft substitutes market segment is estimated to hold major market share in 2020, owing to rising product launches of bone graft substitutes.
North America market is estimated to generate highest revenue share in 2020 in the market during the forecast period.
Stringent government regulatory scenario in research and development of regenerative medicines and post implant failures and infections are the major market restraints.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.